F2G Presents Olorofim Data at IDWeek 2026

MANCHESTER, United Kingdom, Oct. 06, 2026 /CourierPR/ -- F2G Ltd. announced that its abstracts have been accepted for oral and poster presentations at IDWeek 2026, taking place from October 21 to 24, 2026, at the Walter E. Washington Convention Center in Washington, D.C.

The company's Global Phase 3 OASIS data will be presented in a late-breaking oral abstract session. This presentation will focus on the efficacy and safety of olorofim compared to AmBisome®-based standard of care for the treatment of invasive aspergillosis in patients for whom a mold-active azole antifungal is inappropriate or ineffective. The oral presentation will be accompanied by poster presentations that will highlight long-term follow-up data and health-related quality-of-life outcomes in patients with invasive fungal infections who have limited or no treatment options following treatment with olorofim. The OASIS study was a collaboration between F2G and Shionogi & Co. Ltd.

The oral presentation will be given by John H. Rex, MD, Chief Medical Officer of F2G. It is scheduled for Thursday, October 22, 2026, from 10:30 AM to 11:45 AM ET in Room 206.

In addition to the oral presentation, there will be two poster sessions. This poster will be presented by George R. Thompson, MD, Professor of Medicine at the University of California, Davis School of Medicine, on Thursday, October 22, 2026, from 12:15 PM to 1:30 PM ET in Poster Hall B-C.

The second poster session will feature a presentation on the health-related quality of life in patients with invasive fungal infections with limited or no treatment options. This poster will analyze the Phase 2b Olorofim trial data and will be presented by Belinda Lovelace, PharmD, MS, MJ, Executive Director of Health Economics and Outcomes Research at F2G, on Saturday, October 24, 2026, from 12:15 PM to 1:30 PM ET in Poster Hall B-C.

The Phase 3 OASIS study evaluated the efficacy and safety of olorofim versus AmBisome®-based standard of care in adult patients with invasive aspergillosis whose infection is either refractory to or unsuitable for azole therapy. The study was designed as a non-inferiority trial with a non-inferiority margin of 20%, comparing outcomes in 225 subjects randomized 2:1 to olorofim or AmBisome-based standard of care. The primary endpoint was all-cause mortality at Day 42, with additional measures of clinical response, safety, and quality of life.

Study 32 was a multicenter, open-label, Phase 2b study that evaluated the safety and efficacy of olorofim in patients aged 18 years or older with probable pulmonary invasive aspergillosis or proven invasive fungal infections due to Lomentospora prolificans, Scedosporium spp., Aspergillus spp., and other resistant fungi with limited or no treatment options. Patients enrolled between June 2018 and September 2022 received an initial loading dose of 150 mg BID on day one, followed by subsequent oral doses of 90 mg BID for up to 90 days. Patients were followed for another four weeks after the end of treatment, and some received extended therapy for as long as thought clinically beneficial.

Olorofim (formerly F901318) is a first-in-class antifungal with a novel mechanism of action, oral dosing, and activity against a wide range of Aspergillus species, including strains that are resistant to currently approved agents. If approved based on the Phase 3 OASIS data, olorofim will be the first novel mechanism agent for invasive aspergillosis in more than 20 years. In the U.S., olorofim has received orphan drug status from the FDA for the treatment of invasive aspergillosis, scedosporiosis, invasive scopulariopsis, and coccidioidomycosis. Olorofim has also been granted Qualified Infectious Disease Product (QIDP) designation for several invasive fungal infections and has received two Breakthrough Therapy designations from the FDA. In Europe, olorofim has been granted orphan designation from the European Medicines Agency for the treatment of invasive aspergillosis, scedosporiosis, and invasive scopulariopsis.